Journal of Advanced Research · 2024 · 10 citations · 48 references
Life SciencesImmunologyPathologyInflammationInnate ImmunityTransplant ImmunologyAcute RejectionAllograft RejectionGraft RejectionGraft SurvivalInnate Immunity In TransplantationTransplant RejectionAcute Phase ReactantsAllograft Rejection MechanismsGraft Survival EnhancementImmune Response To AllograftImmunologic Response To AllograftInflammatory Response To GraftsOrgan Ischemia-reperfusion InjurySurvival After Allogeneic Transplantation
INTRODUCTION: Despite advancements in transplant immunology and vascularized composite allotransplantation (VCA), the longevity of allografts remains hindered by the challenge of allograft rejection. The acute-phase response, an immune-inflammatory reaction to ischemia/reperfusion that occurs directly after allogeneic transplantation, serves as a catalyst for graft rejection. This immune response is orchestrated by acute-phase reactants through intricate crosstalk with the mononuclear phagocyte system. OBJECTIVE: C-reactive protein (CRP), a well-known marker of inflammation, possesses pro-inflammatory properties and exacerbates ischemia/reperfusion injury. Thus, we investigated how CRP impacts acute allograft rejection. METHODS: Prompted by clinical observations in facial VCAs, we employed a complex hindlimb transplantation model in rats to investigate the direct impact of CRP on transplant rejection. RESULTS: Our findings demonstrate that CRP expedites allograft rejection and diminishes allograft survival by selectively activating non-classical monocytes. Therapeutic stabilization of CRP abrogates this activating effect on monocytes, thereby attenuating acute allograft rejection. Intravital imagining of graft-infiltrating, recipient-derived monocytes during the early phase of acute rejection corroborated their differential regulation by CRP and their pivotal role in driving the initial stages of graft rejection. CONCLUSION: The differential activation of recipient-derived monocytes by CRP exacerbates the innate immune response and accelerates clinical allograft rejection. Thus, therapeutic targeting of CRP represents a novel and promising strategy for preventing acute allograft rejection and potentially mitigating chronic allograft rejection.
48
Monitoring of Blood Vessels and Tissues by a Population of Monocytes with Patrolling Behavior
Cédric Auffray, Darin K. Fogg, Meriem Garfa‐Traoré et al. · Science · 2007 · 1.9K citations
Human CD14dim Monocytes Patrol and Sense Nucleic Acids and Viruses via TLR7 and TLR8 Receptors
Jérôme Cros, Nicolas Cagnard, Kevin Woollard et al. · Immunity · 2010 · 1.2K citations · Full text
Targeting C-reactive protein for the treatment of cardiovascular disease
Mark B. Pepys, Gideon M. Hirschfield, Glenys A. Tennent et al. · Nature · 2006 · 676 citations · Full text
Medicine, Cardiology, Pharmacology +14